Sunshine Biopharma Statistics
Share Statistics
Sunshine Biopharma has 32.93M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 32.93M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.47 and the forward PE ratio is null.
| PE Ratio | -1.47 |
| Forward PE | null |
| PS Ratio | 0.27 |
| Forward PS | null |
| PB Ratio | 0.31 |
| P/FCF Ratio | -0.69 |
| PEG Ratio | n/a |
Enterprise Valuation
Sunshine Biopharma Inc. has an Enterprise Value (EV) of 644.98M.
| EV / Earnings | -143.14 |
| EV / Sales | 26.77 |
| EV / EBITDA | -168.65 |
| EV / EBIT | -134.78 |
| EV / FCF | -67.44 |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.
| Current Ratio | 4.48 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -34.85 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -23.99%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.16% |
| Return on Capital (ROIC) | -23.99% |
| Revenue Per Employee | 547.56K |
| Profits Per Employee | -102.41K |
| Employee Count | 44 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 2.75 |
Taxes
| Income Tax | 395.17K |
| Effective Tax Rate | -0.1 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -1.04, so Sunshine Biopharma 's price volatility has been lower than the market average.
| Beta | -1.04 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.15 |
| 200-Day Moving Average | 0.12 |
| Relative Strength Index (RSI) | 53.51 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of $24.09M and earned -$4.51M in profits. Earnings per share was $-370.41.
| Revenue | 24.09M |
| Gross Profit | 8.34M |
| Operating Income | -4.79M |
| Net Income | -4.51M |
| EBITDA | -3.82M |
| EBIT | -4.79M |
| Earnings Per Share (EPS) | -370.41 |
Balance Sheet
The company has $16.29M in cash and $657.71K in debt, giving a net cash position of $15.63M.
| Cash & Cash Equivalents | 16.29M |
| Total Debt | 657.71K |
| Net Cash | 15.63M |
| Retained Earnings | -63.91M |
| Total Assets | 30.06M |
| Working Capital | 21.45M |
Cash Flow
In the last 12 months, operating cash flow was -$8.78M and capital expenditures -$788.10K, giving a free cash flow of -$9.56M.
| Operating Cash Flow | -8.78M |
| Capital Expenditures | -788.10K |
| Free Cash Flow | -9.56M |
| FCF Per Share | -786.12 |
Margins
Gross margin is 34.61%, with operating and profit margins of -19.86% and -18.7%.
| Gross Margin | 34.61% |
| Operating Margin | -19.86% |
| Pretax Margin | -17.06% |
| Profit Margin | -18.7% |
| EBITDA Margin | -15.87% |
| EBIT Margin | -19.86% |
| FCF Margin | -39.69% |
Dividends & Yields
SBFMW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for SBFMW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -1.01 |
| Piotroski F-Score | 3 |